Lifeward Secures $5.58M in Initial Tranche of $11.16M Convertible Note and Warrant Financing at a Discount
LFWD has more than doubled off its 52-week low of $4.14 on elevated volume (4.4× avg).
Summary
Lifeward Ltd. has secured an initial $5.58 million in a highly dilutive convertible note and warrant financing, with an additional $5.58 million contingent on performance, to address its 'going concern' warning.
Key Events · Financing and Capital Events · LFWD
-
Secured $5.58M Initial Financing
Lifeward Ltd. received an initial $5.58 million from a new securities purchase agreement, consisting of senior secured convertible notes and warrants.
-
Potential Additional $5.58M Contingent on Performance
A second tranche of $5.58 million is available, subject to achieving a 150% increase in ReWalk Unit Sales or the stock price exceeding $13.80 for 10 consecutive trading days.
-
Dilutive Terms at a Discounted Price
The conversion and exercise price for the notes and warrants is $5.40 per share, a significant discount compared to the current stock price of $8.45. This is highly dilutive for existing shareholders.
-
Addresses 'Going Concern' Warning
This financing provides critical capital for the company, which had previously issued a 'going concern' warning in its Q1 2026 earnings report and 10-Q filing.
Analysis · LFWD · Industrial Applications And Services
Lifeward Ltd. has secured a critical financing package totaling up to $11.16 million, with an initial $5.58 million received immediately. This financing, structured as senior secured convertible notes and accompanying warrants, is crucial for the company, which recently reaffirmed a 'going concern' warning. However, the terms are highly dilutive for existing shareholders, as the conversion and exercise price is set at $5.40 per share, a significant discount to the current market price of $8.45. An additional $5.58 million is contingent on achieving specific performance milestones, such as a 150% increase in ReWalk Unit Sales or the stock price exceeding $13.80 for ten consecutive trading days. The notes carry an 8% interest rate, escalating to 15% upon default, and the issuance of underlying shares is subject to a 19.99% exchange cap without further shareholder approval. Oramed Pharmaceuticals Inc., a major existing shareholder, is involved as a collateral agent in this transaction, indicating their continued support but also the challenging nature of the capital raise.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFWD was trading at $8.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $23.8M. The 52-week trading range was $4.14 to $10.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.